The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II study of gemcitabine (G) alone or with pazopanib (P) in refractory soft tissue sarcoma (STS).
 
Christopher W. Ryan
Consulting or Advisory Role - Deciphera; Eisai; Janssen; Pfizer
Research Funding - Argos Therapeutics (Inst); Bristol-Myers Squibb (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline/Novartis (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Pfizer (Inst); TRACON Pharma (Inst); Xynomic Pharma (Inst)
 
Catherine Degnin
No Relationships to Disclose
 
Lee D. Cranmer
Consulting or Advisory Role - Blueprint Medicines; Daiichi Sankyo; Regeneron
Research Funding - AADi (Inst); Advenchen Laboratories (Inst); CBA Research (Inst); Exelixis (Inst); Iterion Therapeutics (Inst); Lilly (Inst); Philogen (Inst)
 
Yiyi Chen
Employment - Biotronik International (I)
 
Seth Pollack
Consulting or Advisory Role - Amgen; Bayer; Daiichi Sankyo; GlaxoSmithKline; Lilly; Nektar; Omeros; PureTech; Tempus
Research Funding - EMD Serono (Inst); Janssen Oncology (Inst); Juno Therapeutics (Inst); Merck (Inst); OncoSec (Inst); Presage Biosciences (Inst)
Travel, Accommodations, Expenses - Lilly/ImClone
 
Jesse Tonkinson
No Relationships to Disclose
 
Phillip Norr
No Relationships to Disclose
 
Lara E. Davis
Consulting or Advisory Role - Epizyme; Epizyme